MedWatch

Biogen's Alzheimer's drug Aduhelm faces EU rejection

Biogen hasn't won support to have its Alzheimer's treatment Aduhelm marketed in the EU, as the drug has received a negative opinion in a trend vote from the EMA's expert committee, the CHMP. The formal rejection of Biogen's marketing authorization application is expected in December.

Photo: POOL New/VIA REUTERS / X80003

The controversial approval of Biogen's drug Aduhelm (aducanumab) in the US hasn't been followed by a corresponding approval in the EU, the company itself reports in a press release on Wednesday.

An oral presentation held by Biogen in November was followed by a so-called trend vote from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). It resulted in members of the committee adopting a negative opinion on the drug and thus no backing for a potential marketing approval in the EU. A formal rejection is expected to be announced at the CHMP's monthly meeting in December.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs